Sly Saint
Senior Member (Voting Rights)
Real-world studies no substitute for RCTs in establishing efficacy
January 19, 2019
https://www.thelancet.com/journals/...&hss_channel=tw-27013292#.XEgvxfcH2L0.twitter
full paper here:
http://sci-hub.tw/https://doi.org/10.1016/S0140-6736(18)32840-X
(retweeted by Michael Sharpe; hmm)
January 19, 2019
1
We live in the real world, so it is reasonable to expect that data collected from the real world should help identify effective therapies. Indeed, rapid increases in the availability of registries, electronic health records, and insurance claims, and the ability to access, process, link, and analyse data from these sources at fairly low cost lend support for calls to replace randomised controlled trials (RCTs) with so-called real-world studies to establish the efficacy of a therapy,
2
, particularly for common serious diseases with abundant, easily collected data such as diabetes.
3
This push is driven partly by the need to show payers that therapies are working and are therefore of value when used in the real world.
4
Other driving factors include the industry's wish to reduce costs and time to get results, a mistaken belief that real-world data are somehow more relevant than RCT data for establishing efficacy, and the ease and speed with which registry data can be accessed and publications generated. However, even with the use of sophisticated methods to address various sources of bias,
5
the absence of randomisation
6
precludes protection from confounding and can lead payers and clinicians alike to erroneously infer that a therapy is beneficial or harmful.
https://www.thelancet.com/journals/...&hss_channel=tw-27013292#.XEgvxfcH2L0.twitter
full paper here:
http://sci-hub.tw/https://doi.org/10.1016/S0140-6736(18)32840-X
(retweeted by Michael Sharpe; hmm)